Sophie Lanzkron
Director, Cardeza Foundation for Hematologic Research · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
Credentials: · · · · · ·
History
PresentSIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY · Thomas Jefferson University
- 2009
John Hopkins Bloomberg School of Public Health
- 1996–1997
John Hopkins School of Medicine
1987–1991
Research
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members
Review · JAMA · 2014 · 1,181 citations
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease
New England Journal of Medicine · 2018 · 451 citations
Blood · 2012 · 356 citations
- LP
35 papers
25 papers
- MB
25 papers
22 papers
- JK
18 papers
15 papers
11 papers
- JS
11 papers
Grants
- 2025–2029
National Heart, Lung, and Blood Institute · R01
PI · $1.4M · Univ of North Carolina Chapel Hill
- 2018–2020
Anti-Mullerian Hormone in the Female Participants of the Multi-Center Study of Hydroxyurea
National Heart, Lung, and Blood Institute · R21
Contact PI · $245.6K · Johns Hopkins University
- 2013–2016
Improving Access to Hydroxyurea for Adults with Sickle Cell Disease
National Heart, Lung, and Blood Institute · R34
Contact PI · $706.5K · Johns Hopkins University
- 2008–2014
Sickle Cell Disease: First Steps Toward Understanding Barriers to Care for Adults
National Heart, Lung, and Blood Institute · K23
Contact PI · $700.7K · Johns Hopkins University
Clinical trials
- 2021–2023
COVID-19 Vaccine Response in Sickle Cell Disease
Principal investigator · Completed
ASH Research Collaborative
- 2018–2022
Assessing the Safety of Buprenorphine in People With Sickle Cell Disease
Principal investigator · Completed · Phase 2
Johns Hopkins University
- 2007–2009
Principal investigator · Withdrawn · Phase 2
Johns Hopkins University
- 2026–2027
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
Site PI · Recruiting · Phase 2
University of California, San Francisco